Baolingbao Biology Co.,Ltd. (SHE:002286)
China
· Delayed Price · Currency is CNY 10.17
-0.01 (-0.10%)
Apr 29, 2026, 3:04 PM CST
Baolingbao Biology Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Net Income | 154.4 | 150.63 | 111.16 | 53.97 | 133.17 | 201.58 | Upgrade
|
| Depreciation & Amortization | 120.31 | 120.31 | 119.52 | 122.74 | 105.63 | 104.98 | Upgrade
|
| Other Amortization | 11.78 | 11.78 | 11.25 | 8.02 | 4.13 | 5.09 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | -0.41 | 0.05 | 0.05 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 6.7 | 6.7 | 30.22 | 12.74 | 4.36 | 3.57 | Upgrade
|
| Loss (Gain) From Sale of Investments | -1.96 | -1.96 | -1.9 | -1.9 | -5.92 | -25.27 | Upgrade
|
| Other Operating Activities | 4.08 | 6.78 | 7.81 | 22.59 | 14.37 | 21.23 | Upgrade
|
| Change in Accounts Receivable | -79.44 | -79.44 | -6.76 | 16.25 | 66.22 | -84.75 | Upgrade
|
| Change in Inventory | -36.76 | -36.76 | -17.05 | 49.79 | -53.48 | -70.67 | Upgrade
|
| Change in Accounts Payable | 71.26 | 71.26 | 7.33 | 15.49 | -237.66 | 51.66 | Upgrade
|
| Change in Other Net Operating Assets | 15.52 | 15.52 | -6.81 | -16.87 | - | - | Upgrade
|
| Operating Cash Flow | 260.44 | 259.36 | 248.72 | 282.28 | 30.82 | 206.27 | Upgrade
|
| Operating Cash Flow Growth | 5.27% | 4.28% | -11.89% | 815.86% | -85.06% | -48.23% | Upgrade
|
| Capital Expenditures | -203.82 | -189.3 | -189.93 | -152.23 | -254.55 | -92.85 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.19 | 0.19 | - | 0.09 | 0.06 | 0.83 | Upgrade
|
| Investment in Securities | -24.79 | -2.8 | 30.59 | 1 | 119.49 | -99.75 | Upgrade
|
| Other Investing Activities | 88.31 | 88.31 | - | 3.04 | 5.31 | 16.26 | Upgrade
|
| Investing Cash Flow | -140.1 | -103.59 | -159.34 | -148.09 | -129.68 | -175.51 | Upgrade
|
| Long-Term Debt Issued | - | 274.6 | 349.8 | 289.58 | 543.8 | 452.14 | Upgrade
|
| Total Debt Issued | 239.7 | 274.6 | 349.8 | 289.58 | 543.8 | 452.14 | Upgrade
|
| Long-Term Debt Repaid | - | -431.6 | -371.26 | -502.69 | -440.46 | -301.52 | Upgrade
|
| Total Debt Repaid | -374.3 | -431.6 | -371.26 | -502.69 | -440.46 | -301.52 | Upgrade
|
| Net Debt Issued (Repaid) | -134.6 | -157 | -21.46 | -213.11 | 103.34 | 150.62 | Upgrade
|
| Issuance of Common Stock | 40.56 | 40.56 | - | - | - | 18.7 | Upgrade
|
| Repurchase of Common Stock | - | - | -7.06 | -7.28 | -0.69 | - | Upgrade
|
| Common Dividends Paid | -30.78 | -31.93 | -55.31 | -49.76 | -52.51 | -38.95 | Upgrade
|
| Other Financing Activities | -1.95 | -1.89 | 2.15 | - | 13 | 4 | Upgrade
|
| Financing Cash Flow | -126.77 | -150.26 | -81.68 | -270.14 | 63.14 | 134.37 | Upgrade
|
| Foreign Exchange Rate Adjustments | -5.81 | 0.59 | 5.54 | 0.09 | 3.73 | -3.29 | Upgrade
|
| Net Cash Flow | -12.24 | 6.1 | 13.24 | -135.86 | -31.99 | 161.84 | Upgrade
|
| Free Cash Flow | 56.63 | 70.07 | 58.79 | 130.05 | -223.72 | 113.42 | Upgrade
|
| Free Cash Flow Growth | 99.37% | 19.18% | -54.79% | - | - | -57.45% | Upgrade
|
| Free Cash Flow Margin | 2.01% | 2.55% | 2.45% | 5.15% | -8.25% | 4.10% | Upgrade
|
| Free Cash Flow Per Share | 0.15 | 0.19 | 0.16 | 0.36 | -0.60 | 0.30 | Upgrade
|
| Cash Income Tax Paid | 33.96 | 30.81 | 15.04 | -23.95 | -12.31 | 18.05 | Upgrade
|
| Levered Free Cash Flow | 45.27 | 43.46 | -5.68 | -30.89 | -372.39 | 67.94 | Upgrade
|
| Unlevered Free Cash Flow | 45.27 | 43.46 | 2.47 | -16.72 | -355.8 | 78.53 | Upgrade
|
| Change in Working Capital | -34.87 | -34.87 | -28.92 | 64.07 | -224.95 | -104.91 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.